Shi Menglong, Sun Tianye, Ji Zhaochen, Ma Yucong, Zhao Min, Yang Fengwen, Zhang Junhua
State Key Laboratory of Component-Based Chinese Medicine, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Evidence-Based Medicine Center, College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Front Pharmacol. 2023 Sep 18;14:1265603. doi: 10.3389/fphar.2023.1265603. eCollection 2023.
Coronary heart disease (CHD) poses a serious threat to public health, and the current medical management still faces significant challenges. Reliable evidence on the efficacy of Shuxuening injection (SXNI) in CHD is still lacking, even though it is widely used in China. To evaluate the efficacy of SXNI combination therapy in treating CHD. A systematic search of eight databases was conducted to identify relevant randomized controlled trials (RCTs) from the inception of each database until June 2023. ROB 2.0, RevMan 5.4, and Stata 15.1 were used for quality evaluation and data analysis. The Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) approach was used to evaluate the quality of evidence. A total of 3,779 participants from 39 studies were included. The results showed SXNI combination therapy increased the clinical efficacy and decreased the frequency and duration of angina. Furthermore, SXNI combination therapy improved cardiac function of patients by decreasing LVEDD, and increased CI, CO, and LVEF. It also improved blood lipid profiles by increasing HDL, decreasing TC, TG, and LDL. The thrombosis factors of patients were also improved by decreasing FIB, PV, HCT, and HS. Moreover, SXNI combination therapy was superior to the conventional treatment in improving CRP levels, increasing ECG efficacy and BNP. However, due to the limited safety information, reliable safety conclusions could not be drawn. Furthermore, the levels of evidence ranged from very low to moderate due to publication bias and heterogeneity. SXNI can effectively improve angina symptoms, clinical efficacy, cardiac function, blood lipid indicators, and thrombosis factors of patients with CHD. However, more multi-center and large-sample studies are needed to confirm the conclusions due to the limitations of this study. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606; Identifier: CRD42023433292.
冠心病（CHD）对公众健康构成严重威胁，目前的医疗管理仍面临重大挑战。尽管舒血宁注射液（SXNI）在中国被广泛使用，但关于其治疗冠心病疗效的可靠证据仍然缺乏。为了评估SXNI联合疗法治疗冠心病的疗效。对八个数据库进行了系统检索，以识别从每个数据库建立至2023年6月的相关随机对照试验（RCT）。使用ROB 2.0、RevMan 5.4和Stata 15.1进行质量评估和数据分析。采用推荐分级、评估、制定和评价（GRADE）方法评估证据质量。共纳入了39项研究的3779名参与者。结果显示，SXNI联合疗法提高了临床疗效，降低了心绞痛的频率和持续时间。此外，SXNI联合疗法通过降低左心室舒张末期内径（LVEDD）改善了患者的心功能，并增加了心脏指数（CI）、心输出量（CO）和左心室射血分数（LVEF）。它还通过增加高密度脂蛋白（HDL）、降低总胆固醇（TC）、甘油三酯（TG）和低密度脂蛋白（LDL）改善了血脂谱。患者的血栓形成因素也通过降低纤维蛋白原（FIB）、血小板体积（PV）、红细胞压积（HCT）和高敏C反应蛋白（HS）得到改善。此外，SXNI联合疗法在改善C反应蛋白（CRP）水平、提高心电图疗效和脑钠肽（BNP）方面优于传统治疗。然而，由于安全性信息有限，无法得出可靠的安全性结论。此外，由于发表偏倚和异质性，证据水平从极低到中等不等。SXNI可以有效改善冠心病患者的心绞痛症状、临床疗效、心功能、血脂指标和血栓形成因素。然而，由于本研究的局限性，需要更多的多中心和大样本研究来证实这些结论。https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=399606；标识符：CRD42023433292。
Zotero 插件
